Inhibition of HSP90 and Activation of HSF1 Diminish Macrophage NLRP3 Inflammasome Activity in Alcohol-Associated Liver Injury.


Journal

Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242

Informations de publication

Date de publication:
06 2020
Historique:
received: 23 12 2019
accepted: 31 03 2020
pubmed: 14 4 2020
medline: 15 12 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

Activation of NLRP3 in liver macrophages contributes to alcohol-associated liver disease (ALD). Molecular chaperone heat shock protein (HSP) 90 facilitates NLRP3 inflammasome activity during infections and inflammatory diseases. We previously reported that HSP90 is induced in ALD and regulates proinflammatory cytokines, tumor necrosis factor alpha, and IL-6. Whether HSP90 affects IL-1β and IL-18 regulated by NLRP3 inflammasome in ALD is unknown. Here, we hypothesize that HSP90 modulated NLRP3 inflammasome activity and affects IL-1β and IL-18 secretion in ALD. The expression of HSP90AA1 and NLRP3 inflammasome genes was evaluated in human alcoholic livers and in mouse model of ALD. The importance of HSP90 on NLRP3 inflammasome activation in ALD was evaluated by administering HSP90 inhibitor, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) to mice subjected to ALD, and in vitro to bone marrow-derived macrophages (BMDM) stimulated with LPS and ATP. The effect of activation of HSF1/HSPA1A axis during HSP90 inhibition or direct activation during heat shock of BMDMs on NLRP3 activity and secretion of downstream cytokines was evaluated. We found positive correlation between induction of HSP90 and NLRP3 inflammasome genes in human alcoholic cirrhotic livers. Administration of 17-DMAG in mouse model of ALD significantly down-regulated NLRP3 inflammasome-mediated caspase-1 (CASP-1) activity and cytokine secretion, with reduction in ALD. 17-DMAG-mediated decrease in NLRP3 was restricted to liver macrophages. Using BMDMs, we show that inhibition of HSP90 prevented CASP-1 activity, and Gasdermin D (GSDMD) cleavage, important in release of active IL-1β and IL-18. Interestingly, activation of the heat shock factor 1 (HSF1)/HSPA1A axis, either during HSP90 inhibition or by heat shock, decreased NLRP3 inflammasome activity and reduced secretion of cytokines. Our studies indicate that inhibition of HSP90 and activation of HSF1/HSPA1A reduce IL-1β and IL-18 via decrease in NLRP3/CASP-1 and GSDMD activity in ALD.

Sections du résumé

BACKGROUND
Activation of NLRP3 in liver macrophages contributes to alcohol-associated liver disease (ALD). Molecular chaperone heat shock protein (HSP) 90 facilitates NLRP3 inflammasome activity during infections and inflammatory diseases. We previously reported that HSP90 is induced in ALD and regulates proinflammatory cytokines, tumor necrosis factor alpha, and IL-6. Whether HSP90 affects IL-1β and IL-18 regulated by NLRP3 inflammasome in ALD is unknown. Here, we hypothesize that HSP90 modulated NLRP3 inflammasome activity and affects IL-1β and IL-18 secretion in ALD.
METHODS
The expression of HSP90AA1 and NLRP3 inflammasome genes was evaluated in human alcoholic livers and in mouse model of ALD. The importance of HSP90 on NLRP3 inflammasome activation in ALD was evaluated by administering HSP90 inhibitor, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) to mice subjected to ALD, and in vitro to bone marrow-derived macrophages (BMDM) stimulated with LPS and ATP. The effect of activation of HSF1/HSPA1A axis during HSP90 inhibition or direct activation during heat shock of BMDMs on NLRP3 activity and secretion of downstream cytokines was evaluated.
RESULTS
We found positive correlation between induction of HSP90 and NLRP3 inflammasome genes in human alcoholic cirrhotic livers. Administration of 17-DMAG in mouse model of ALD significantly down-regulated NLRP3 inflammasome-mediated caspase-1 (CASP-1) activity and cytokine secretion, with reduction in ALD. 17-DMAG-mediated decrease in NLRP3 was restricted to liver macrophages. Using BMDMs, we show that inhibition of HSP90 prevented CASP-1 activity, and Gasdermin D (GSDMD) cleavage, important in release of active IL-1β and IL-18. Interestingly, activation of the heat shock factor 1 (HSF1)/HSPA1A axis, either during HSP90 inhibition or by heat shock, decreased NLRP3 inflammasome activity and reduced secretion of cytokines.
CONCLUSION
Our studies indicate that inhibition of HSP90 and activation of HSF1/HSPA1A reduce IL-1β and IL-18 via decrease in NLRP3/CASP-1 and GSDMD activity in ALD.

Identifiants

pubmed: 32282939
doi: 10.1111/acer.14338
pmc: PMC7328660
mid: NIHMS1591517
doi:

Substances chimiques

Benzoquinones 0
Cytokines 0
Gsdma protein, mouse 0
HSF1 protein, human 0
HSP90 Heat-Shock Proteins 0
HSP90AA1 protein, human 0
Heat Shock Transcription Factors 0
Hsf1 protein, mouse 0
IL1B protein, mouse 0
Interleukin-18 0
Interleukin-1beta 0
Lactams, Macrocyclic 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NLRP3 protein, human 0
Neoplasm Proteins 0
Nlrp3 protein, mouse 0
RNA, Messenger 0
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 001L2FE0M3
Caspase 1 EC 3.4.22.36

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1300-1311

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA017986
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025289
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146855
Pays : United States
Organisme : National Institute of Alcohol Abuse and Alcoholism
ID : R01 AA25289-01
Pays : International

Informations de copyright

© 2020 by the Research Society on Alcoholism.

Références

N Engl J Med. 2011 Nov 10;365(19):1790-800
pubmed: 22070476
Hepatology. 2016 Nov;64(5):1683-1698
pubmed: 27474884
Cell Microbiol. 2008 Dec;10(12):2434-46
pubmed: 18671821
Leuk Lymphoma. 2017 Apr;58(4):923-931
pubmed: 27686857
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Trends Biochem Sci. 2016 Dec;41(12):1012-1021
pubmed: 27669650
J Biol Chem. 2002 Apr 5;277(14):11802-10
pubmed: 11801594
Antioxid Redox Signal. 2011 Jul 15;15(2):523-34
pubmed: 21126203
Hepatology. 2016 Sep;64(3):955-65
pubmed: 26773297
Nat Protoc. 2013 Mar;8(3):627-37
pubmed: 23449255
J Leukoc Biol. 2015 Aug;98(2):249-56
pubmed: 25934928
Hepatology. 2012 May;55(5):1585-95
pubmed: 22105779
Front Mol Neurosci. 2018 Nov 06;11:401
pubmed: 30459553
IUBMB Life. 1999 Oct;48(4):429-33
pubmed: 10632574
Redox Biol. 2015;4:296-307
pubmed: 25625584
Sci Rep. 2018 Apr 30;8(1):6720
pubmed: 29712950
Neuron. 2019 Jan 16;101(2):207-223.e10
pubmed: 30606613
Eur J Immunol. 2018 Apr;48(4):584-592
pubmed: 29274245
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2835-40
pubmed: 25730877
Biopolymers. 2016 Aug;105(8):594-607
pubmed: 26991466
Nat Commun. 2019 Jul 16;10(1):3126
pubmed: 31311938
J Immunol. 2014 Aug 15;193(4):1975-87
pubmed: 25024384
Immunity. 2018 Jan 16;48(1):35-44.e6
pubmed: 29195811
J Hepatol. 2018 Mar;68(3):586-592
pubmed: 28966126
Nat Immunol. 2007 May;8(5):497-503
pubmed: 17435760
Hepatology. 2016 Oct;64(4):1343-55
pubmed: 26940353
Nat Rev Drug Discov. 2018 Aug;17(8):588-606
pubmed: 30026524
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Hepatol. 2014 Oct;61(4):903-11
pubmed: 24859453
Methods Mol Biol. 2018;1709:423-441
pubmed: 29177675
J Clin Invest. 2012 Oct;122(10):3476-89
pubmed: 22945633
Annu Rev Pharmacol Toxicol. 2015;55:353-71
pubmed: 25292434

Auteurs

Asmita Choudhury (A)

From the, Department of Medicine, (AC, DB, AL, PM), University of Massachusetts Medical School, Worcester, Massachusetts.

Daniel Bullock (D)

From the, Department of Medicine, (AC, DB, AL, PM), University of Massachusetts Medical School, Worcester, Massachusetts.

Arlene Lim (A)

From the, Department of Medicine, (AC, DB, AL, PM), University of Massachusetts Medical School, Worcester, Massachusetts.

Josepmaria Argemi (J)

Division of Gastroenterology, Hepatology and Nutrition, (JA, RB), Pittsburgh Liver Research Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Pontus Orning (P)

Program in Innate Immunity, (PO, EL), Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Department of Clinical and Molecular Medicine, (PO, EL), Centre of Molecular Inflammation Research, NTNU, Trondheim, Norway.

Egil Lien (E)

Program in Innate Immunity, (PO, EL), Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Department of Clinical and Molecular Medicine, (PO, EL), Centre of Molecular Inflammation Research, NTNU, Trondheim, Norway.

Ramon Bataller (R)

Division of Gastroenterology, Hepatology and Nutrition, (JA, RB), Pittsburgh Liver Research Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Pranoti Mandrekar (P)

From the, Department of Medicine, (AC, DB, AL, PM), University of Massachusetts Medical School, Worcester, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH